ArticlePloS one2019

Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.

Darrell H S Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.